Glucagon-like Peptide-1 Receptor Agonists: Are They as Good as They Seem? A Systematic Review of Severe Adverse Effects
As obesity evolves as a global pandemic, the use of drugs to treat it is booming. The latest among these are Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Along with their use, the incidence of adverse events has become more common. Although severe effects have been mentioned, details and a...
Gardado en:
| Principais autores: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
MDPI AG
2024-08-01
|
| Series: | Endocrines |
| Assuntos: | |
| Acceso en liña: | https://www.mdpi.com/2673-396X/5/3/23 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|